Rescue of Influenza C Virus from Recombinant DNA by Crescenzo-Chaigne, Bernadette & Van Der Werf, Sylvie
Rescue of Influenza C Virus from Recombinant DNA
Bernadette Crescenzo-Chaigne, Sylvie Van Der Werf
To cite this version:
Bernadette Crescenzo-Chaigne, Sylvie Van Der Werf. Rescue of Influenza C Virus from Re-
combinant DNA. Journal of Virology, American Society for Microbiology, 2007, 81, pp.11282 -
11289. <10.1128/JVI.00910-07>. <pasteur-01103993>
HAL Id: pasteur-01103993
https://hal-pasteur.archives-ouvertes.fr/pasteur-01103993
Submitted on 15 Jan 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
JOURNAL OF VIROLOGY, Oct. 2007, p. 11282–11289 Vol. 81, No. 20
0022-538X/07/$08.000 doi:10.1128/JVI.00910-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Rescue of Influenza C Virus from Recombinant DNA
Bernadette Crescenzo-Chaigne and Sylvie van der Werf*
Unite´ de Ge´ne´tique Mole´culaire des Virus Respiratoires, URA 1966 CNRS, EA 302 Universite´ Paris Diderot,
Institut Pasteur, Paris, France
Received 28 April 2007/Accepted 30 July 2007
The rescue of influenza viruses by reverse genetics has been described only for the influenza A and B
viruses. Based on a similar approach, we developed a reverse-genetics system that allows the production
of influenza C viruses entirely from cloned cDNA. The complete sequences of the 3 and 5 noncoding
regions of type C influenza virus C/Johannesburg/1/66 necessary for the cloning of the cDNA were
determined for the seven genomic segments. Human embryonic kidney cells (293T) were transfected
simultaneously with seven plasmids that direct the synthesis of each of the seven viral RNA segments of
the C/JHB/1/66 virus under the control of the human RNA polymerase I promoter and with four plasmids
encoding the viral nucleoprotein and the PB2, PB1, and P3 proteins of the viral polymerase complex. This
strategy yielded between 103 and 104 PFU of virus per ml of supernatant at 8 to 10 days posttransfection.
Additional viruses with substitutions introduced in the hemagglutinin-esterase-fusion protein were suc-
cessfully produced by this method, and their growth phenotype was evaluated. This efficient system, which
does not require helper virus infection, should be useful in viral mutagenesis studies and for generation
of expression vectors from type C influenza virus.
The influenza C virus, a member of the Orthomyxoviridae
family, was first isolated in 1947 and is a common cause of mild
upper respiratory tract illness. Seroepidemiology studies indi-
cate that this virus is widely distributed around the world and
that the majority of humans acquire antibodies against the
virus early in life (30). The disease caused by it tends to take an
unapparent or very mild course, so that the virus is only ex-
ceptionally isolated (29). Furthermore, analysis of the genome
sequence of type C influenza viruses isolated over time sug-
gested that reassortment between two different type C influ-
enza viruses occurs frequently in nature (4, 31).
It has long been believed that unlike the case for influenza A
virus, humans are the only natural host for influenza C viruses
(1). Guo et al. (13) succeeded in isolating a number of influ-
enza C viruses from abattoir pigs in Beijing, China, and dem-
onstrated pig-to-pig transmission of the virus upon experimen-
tal infection. The presence of specific antibodies was also
demonstrated in the serum of pigs in Japan and Great Britain
(3, 55). Furthermore, human influenza C virus isolates were
found to be closely related to pig isolates, suggesting that
interspecies transmission of influenza C virus between humans
and pigs has occurred in nature (24). Influenza C virus-specific
antibodies were also detected in dogs (26, 27, 39), but detec-
tion or isolation of the virus from this animal species has not
been documented, although experimental infection resulted in
clinical symptoms and viral replication (38). Consequently, in-
fluenza C viruses are not restricted to humans, but the poten-
tial role of pigs or dogs as an animal reservoir for human
influenza C virus remains to be elucidated.
In contrast with those of type A and B influenza viruses, the
type C influenza virus genome consists of only seven segments
of single-stranded RNA of negative polarity, which are num-
bered based on decreasing lengths, i.e., the PB2, PB1, P3,
HEF, NP, M, and NS segments, respectively (reviewed in ref-
erence 42). As for type A and B influenza viruses, each viral
RNA (vRNA) molecule is associated with the nucleoprotein
(NP) and a heterotrimeric polymerase complex (P) that con-
sists of the three polymerase subunits, PB2, PB1, and P3, thus
forming the ribonucleoproteins (RNP). Because the minimal
replication unit is formed by the RNPs, the generation of virus
from cloned cDNAs requires the presence of the seven
vRNAs, as well as that of the four viral proteins, PB2, PB1, P3,
and NP, involved in the transcription and replication of the
viral RNA (6). Reverse-genetics systems that allow the pro-
duction of infectious virus from cloned cDNA have already
been developed for the type A (11, 35) and B (20, 23) influenza
viruses and for the Thogoto virus, a tick-transmitted ortho-
myxovirus (54). Several strategies have been designed. The
primary method was based on the transfection of 12 plasmids:
the 8 full-length cDNAs derived from the viral genome were
cloned into a vRNA expression plasmid between the human
RNA polymerase I promoter and the mouse RNA polymer-
ase I terminator, and the coding regions of the nucleopro-
tein and of the PB2, PB1, and PA viral polymerase proteins
were cloned into a protein expression plasmid to provide the
four viral proteins required for transcription/replication of
the vRNAs (11, 23, 35). The second strategy was based on
the use of bidirectional RNA polymerase I/II plasmids to
clone the full-length cDNAs derived from each of the viral
genomic segments to drive, after transfection, both the ex-
pression of the proteins and the synthesis of each of the
negative-sense vRNAs (20, 21). More recently, Neumann et
al. (34) reduced the number of plasmids required for virus
generation to six, five, three, and even one plasmid. Finally,
a third recently published strategy is based on the use of the
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T7 RNA polymerase promoter, thus allowing the use of a
variety of cell lines (9).
To date, no plasmid-based system for the rescue of influenza
C virus has been reported. Here we describe a reverse-genetics
system for influenza C virus based on the C/Johannesburg/1/66
(C/JHB/1/66) virus strain. Having completed the sequence of
the 3 and 5 noncoding (NC) regions of the seven genomic
segments of this strain, we chose to base our type C influenza
virus reverse-genetics system on the primary method described
above for influenza virus types A and B. Plasmids that direct
expression of the seven vRNAs under the control of the human
RNA polymerase I promoter were thus generated and used
together with the four plasmids that direct the expression of
the NP, PB2, PB1, and P3 proteins previously described (6).
Having set up an efficient reverse-genetics system to rescue
wild-type influenza C virus, we tested its usefulness by engi-
neering influenza C viruses mutated in the hemagglutinin-
esterase-fusion protein (HEF). The spike glycoproteins of the
lipid-enveloped orthomyxoviruses have three functions: to rec-
ognize the receptor on the cell surface, to mediate viral fusion,
and to destroy the receptor. In type A and B influenza viruses,
the first two activities are mediated by the hemagglutinin (HA)
and the third by a second glycoprotein, the neuraminidase
(42). In the case of type C influenza virus, a single glycoprotein,
the HEF protein, possesses all three functions (16). The re-
ceptor recognized by HEF differs from that used by the type A
and B influenza virus HA by the addition of an acetyl group at
the 9-O position of the glycerol side chain of the sialic acid.
More precisely, the influenza C virus utilizes the 9-O-acetyl-
N-acetylneuraminic acid (Neu5,9Ac2) for attachment to the
cell surface (19, 46). Because of the lack of Neu5,9Ac2 in the
cell surface receptors, Madin-Darby canine kidney II cells
(MDCK II cells), which are commonly used for type A and B
influenza viruses, are resistant to infection by type C influenza
virus. However, their resistance can be overcome by coating
the cells with bovine brain gangliosides (BBG), which naturally
contain Neu5,9Ac2 (17). The fusion activity of HEF is depen-
dent on the proteolytic cleavage of a precursor (HEF0) into
HEF1 and HEF2, the largest and smallest proteolytic cleavage
products, respectively (15, 37), and requires activation at a low
pH upon internalization of the viral particle through the en-
dosome pathway. Finally, the acetylesterase activity of HEF
inactivates the virus receptor by releasing the O-acetyl residues
from C-9 of Neu5,9Ac2 (18).
Based on published data on residues that could be critical in
HEF processing or function (14, 44, 45, 50), we chose to focus
on positions 284 and 465 of the HEF protein (amino acid
numbering). Indeed, it has been suggested that position 284 of
HEF could be involved in receptor binding activity (50),
whereas position 465 is located in the peptide fusion domain of
HEF (12). Single and double mutants could be rescued, and
their phenotype was further analyzed and compared to that of
the wild-type virus.
MATERIALS AND METHODS
Cells and viruses. 293T human embryonic kidney cells and MDCK II cells
were maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% and 5% fetal calf serum (FCS), respectively. The MDCK cell line was
isolated in 1958, and two sublines have been described: MDCK I cells, which
derived from an early passage and are susceptible to type C influenza virus, and
MDCK II cells, which predominated in later passages and are resistant to type C
influenza virus because they lack Neu5,9Ac2 (56).
Human skin melanoma cells (SK 93/2) were kindly provided by Frade (Saint
Antoine Hospital, Paris, France) and were maintained in RPMI supplemented
with 5% FCS (40, 43).
All cells were maintained at 37°C in 5% CO2 before transfection or infection.
Influenza C virus C/JHB/1/66, considered the reference strain, was propagated
in 10-day-old embryonated eggs.
Determination of 3 and 5end NC sequences of genomic RNA segments. Viral
genomic RNA was extracted from C/JHB/1/66 using the Trizol reagent (Gibco-
BRL). The 3 and 5 NC sequence were determined as previously described (7)
using an anchored (dT)14 oligonucleotide and primers specific for the coding
sequences of each of the seven type C vRNA segments for reverse transcription
and amplification. After purification, the PCR products were sequenced with
internal oligonucleotides. The exact sequences of the primers used for amplifi-
cation and sequencing of the 3 and 5 NC sequences of each segment are
available from the authors upon request.
Cloning of plasmids. Plasmids pHMG-PB2, -PB1, -P3, and -NP, which direct
expression of the PB2, PB1, P3, and NP proteins of the influenza C virus under
the control of the mouse hydroxymethylglutaryl-coenzyme A reductase pro-
moter, have been described previously (6).
To generate plasmids that direct the synthesis of the seven vRNA segments
from C/JHB/1/66 virus, PCR products corresponding to each of the full-length
segments were cloned in plasmid vector pPR, in which BbsI restriction sites are
flanked by the promoter of the human RNA polymerase I and the hepatitis delta
ribozyme sequence (6). For cloning of the cDNA corresponding to the PB2, P3,
and NP segments, sequences were amplified from the pHMG-PB2, -P3, and -NP
plasmids, respectively, using High Fidelity Enzyme Taq polymerase (Roche) and
primers containing the total 3 and the far-end 5 NC sequences for PB2 and P3
and primers containing the total 3 and partial 5 NC sequences for NP. For the
cloning of cDNA corresponding to the four other segments, C/JHB/1/66 RNA
was reverse transcribed with 300 nM of the C/uni1 primer, 5-AGC AGA AGC
AG, in the presence of 0.4 U/l of avian myeloblastosis virus reverse transcrip-
tase (Promega) at 37°C. The cDNAs were then amplified by PCR using the High
Fidelity Enzyme Taq polymerase for the HEF, M, and NS segments or with the
pfx platinium Taq polymerase (Invitrogen) for the PB1 segment. Specifics prim-
ers containing the 3 and 5 NC sequences were used. For PB1 and HEF, a
two-step strategy was necessary. For both segments, two overlapping PCR prod-
ucts corresponding to both halves of the segment were produced. These were
then used as templates for a second PCR using the outer primers to generate the
full-length cDNA. The 5 end sequences of all primers contained BsmBI sites.
The purified PCR products were then digested with BsmBI and cloned into the
BbsI sites of the pPR vector. The sequences of the primers will be provided upon
request. The resulting vRNA expression plasmids were named pC/PR/X/JHB,
where X corresponds to the name of each segment. To ensure that the genes
were free of nonsilent mutations, several plasmids were sequenced for each
constructions.
Mutations in the HEF gene sequence around nucleotides (nt) 872 and 1414,
resulting in Thr-to-Ile and Thr-to-Ala substitutions at residues 284 and 465,
respectively, were introduced into the pC/PR/HEF/JHB plasmid using the
Quikchange II site-directed mutagenesis kit (Stratagene) according to the man-
ufacturer’s instructions and verified by sequencing. The double mutant was
obtained by subcloning. All plasmids were sequenced using a Big Dye terminator
sequencing kit and an automated sequencer (Perkin-Elmer).
Transfection and rescue of viruses. 293T cells (6  105) seeded on 35 mm
poly-D-lysine plates (Greiner bio-one) in DMEM supplemented with 10% FCS
were transfected with the four protein expression plasmids, allowing the expres-
sion of the NP and the polymerase proteins, and the seven vRNA expression
plasmids, allowing the synthesis of the seven vRNA templates, using 0.5 g of
each plasmid and 10 l of FUGENE 6 (Roche) according to the manufacturer’s
instructions. Briefly, the DNA and the transfection reagent were mixed, incu-
bated at room temperature for 15 min, and then added to the cells and incubated
at 33°C. Sixteen hours later, the DNA transfection reagent was removed and the
cells were washed twice in DMEM and, after addition of 4 ml of DMEM
containing 0.25 g/ml L-1-tosylamido-2-phenyl chloromethyl ketone (TPCK)-
trypsin (Worthington), incubated at 33°C. Eight to 10 days after transfection,
supernatants were collected and the viruses were titrated by plaque assay on
MDCK II cells.
Plaque assay. MDCK II cells were seeded in six-well tissue culture plates (106
cells per well). At 100% confluence, cells were washed twice with phosphate-
buffered saline (PBS) and incubated for at least 45 min at 37°C with 0.4 ml of a
solution of BBG (Sigma) at 0.2 mg/ml in PBS. Then, cells were washed twice in
PBS and incubated with 0.4 ml of each serial dilution of the virus for 30 min at
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room temperature. Finally, each well was covered with 4 ml of a 1 agar overlay
mixture (final concentration, 1% SeaKem GTG agarose [Tebu], 1 DMEM
[Eurobio], 1 g/ml TPCK-trypsin). Plates were then incubated at 33°C with 5%
CO2 for 4 to 5 days: once the plaques were clearly visible, the agar overlay was
carefully removed and the cells stained with 0.3% crystal violet solution and 10%
formaldehyde. Titers were expressed as PFU/ml.
Virus amplification and growth kinetics. SK 93/2 cells were infected with the
transfection supernatant at a multiplicity of infection (MOI) of 103 in RPMI
containing 0.25 g/ml of TPCK-trypsin at 33°C with 5% CO2. Five days after
incubation, the supernatant was titrated by plaque assay on MDCK II cells.
Growth kinetics and analysis of the virus phenotype were performed in duplicate
and triplicate, respectively, with viruses amplified once on SK 93/2 cells. MDCK
II cells incubated with or without BBG were infected at an MOI of 103 in
DMEM containing 0.25 or 5 g/ml of TPCK-trypsin and incubated at 33°C with
5% CO2. The supernatants were collected each day for determining the kinetics
or 4 days after infection for virus phenotype analysis. The virus titers were
determined by plaque assay as described above.
RNA isolation and RT-PCR. To analyze mutations on the HEF protein, viral
RNA was extracted from infectious culture supernatants (140 l) by using the
QIAamp viral RNA kit (QIAGEN, Inc., Valencia, CA) according to the manu-
facturer’s instructions. The RNA was eluted in 60 l of buffer and stored at
80°C. The rescued influenza C viruses were characterized by reverse transcrip-
tion-PCR (RT-PCR). For synthesis of cDNA, viral RNA (5 l) was reverse
transcribed with avian myeloblastosis virus reverse transcriptase in the presence
of primer C/uni1 (0.5 M). A nested PCR was performed to amplify an 875-nt
amplicon in the HEF gene using specific primers (sequences of the four primers
are available upon request). The purified PCR products were analyzed by 1%
agarose gel electrophoresis before and after digestion with EcoRV or NgoMIV.
Nucleotide sequence accession numbers. The GenBank/EMBL/DDJ accession
numbers are AF170573, AF170574, AF170575, and AF170576 for the NP, P3,
PB1, and PB2 segments, respectively, and AM410041, AM410042, and
AM410043 for the HEF, M, and NS segments, respectively.
RESULTS
Complete sequences of 3 and 5 NC regions of genomic
RNA segments from influenza virus C/Johannesburg/1/66. As
a first step in generating a reverse-genetics system for influenza
C virus, we determined the complete sequences of the 3 and
5 NC regions of the seven segments of the virus C/JHB/1/66/.
Indeed, very few complete 3 and 5 NC sequences are avail-
able in the GenBank database and not for all segments of the
same virus. In the early 1980s, only partial nucleotide se-
quences of the 3 and 5 NC regions were determined for the
seven genomic segments of C/JHB/1/66 virus by Desselberger
et al. (8). The only complete NC sequences of C/JHB/1/66 in
the databases were those of the HEF segment (accession num-
bers M17868 and AY880247) (14). In 1984, Clern-van Haaster
and Meier-Ewert (5) also published partial 3 NC sequences
for two other type C virus isolates. Our sequences showed that
at the 3 end, the first 11 nt as well as nt 14 were conserved for
the seven segments of C/JHB/1/66. Similarly, at the 5 end, the
first 12 nt and nt 15 were found to be conserved among the
seven segments except for the NS segment, for which the U
residue at nt 6 was replaced by a G. This was already described
for the 5 end of the NS segment of the C/California/78 virus
(accession number M10087).
Cloning of cDNAs of the seven vRNA segments of C/JHB/
1/66 influenza virus. To generate the vRNA expression plas-
mids, the cDNAs corresponding to the seven full-length
genomic segments of influenza C virus C/JHB/1/66 were
cloned as described in Materials and Methods.
The sequences of the different clones were then compared
with those available in the GenBank database, including our
own previous sequences (6). No difference in the nucleotide
sequence was found for the PB2, PB1, P3, and NP segments.
One nucleotide difference was found for the M segment com-
pared with the sequence available in the database (accession
number AB000604), but this mutation was silent.
Out of the five nucleotide differences found between our
sequence and previously published sequences of HEF of
C/JHB/1/66 (14), only position 1414 resulted in a Thr-to-Ala
substitution at position 465.
For the NS segment, we confirmed the observation made by
Marschall et al. (28) and Alamgir et al. (2): i.e., the presence of
an additional G residue at position 701 compared with the
sequence of C/JHB/1/66 published in 1986 (accession number
D00031). Eleven other differences were found with that 1986
sequence, most of them silent (data not shown). When com-
paring our C/JHB/1/66 NS sequence with that of C/JHB/4/67
published more recently by Alamgir (2), six nucleotide differ-
ences were found, three of which were nonsilent mutations
that resulted in four amino acid substitutions, two in NS1
(amino acids [aa] 74 and 228) and two in NS2 (aa 124 and 144).
Rescue of infectious influenza C virus from cloned cDNAs.
The 293T cell line is very easily transfectable but lowly adher-
ent and extremely sensitive to the concentration of trypsin
which is required for the cleavage of the HEF glycoprotein
(14). We therefore cultured 293T cells on poly-lysine plates to
improve the adhesion of the cells and limit their sensitivity to
trypsin. A concentration of TPCK-trypsin of 0.25 g/ml was
found to be optimal to maintain the 293T cell adherence and
to obtain viral titers up to 105 to 106 PFU/ml after an infection
at an MOI of 103 with influenza C virus (data not shown).
Furthermore, we observed that the 293T cells had to be 70 to
80% confluent before transfection, and thus, we decided to use
all of these conditions to build our reverse-genetics system for
influenza C virus.
To produce infectious influenza C virus entirely from cloned
cDNAs, the seven plasmids that direct the synthesis of each of
the full-length viral RNAs were transfected into 293T cells
along with the expression plasmids that encode the three poly-
merase subunits and NP protein.
For three representative experiments, we could detect be-
tween 103 and 104 PFU/ml of rescued virus in the supernatant
of the transfected cells at 8 or 10 days after transfection (Table
1). Upon amplification on the permissive cell line SK 93/2,
titers of 105 to 106 PFU/ml were reached. Similarly, the virus
was readily amplified on embryonated eggs to titers of 109
PFU/ml. Furthermore, the virus was successfully recovered for
five consecutive passages on SK 93/2 cells (data not shown).
TABLE 1. Generation of type C influenza viruses following plasmid
transfection of 293T cells
Virusa
Titer of virusb (PFU/ml)
Expt 1 Expt 2 Expt 3
wt 1.3  103 2.5  104 1.2  104
284 2.5  105 6  104
465 1.5  103 2.25  104 1  104
284465 7.5  104 105
a Rescued viruses: wt, wild-type-like; 284, 284 Ile mutant; 465, 465 Ala mutant;
284465, 284 Ile and 465 Ala double mutant.
b Titers from transfection supernatants as determined by plaque assay with
MDCK II cells. For 284 and 284465 viruses, only two experiments were per-
formed.
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For each transfection, an attempt without the HEF vRNA
expression plasmid was performed as a negative control and no
virus could be rescued (data not shown).
Generation of infectious influenza C viruses harboring mu-
tations in the HEF gene. To further validate our reverse-
genetics procedure, we explored the possibility of engineering
C/JHB/1/66 viruses with mutations in the HEF gene. In 1989,
Szepanski et al. (51) obtained a mutant of C/JHB/1/66 able to
grow on MDCK II cells in the presence of a high concentration
of trypsin. A single mutation at nt 872 of the HEF segment,
resulting in a Thr-to-Ile substitution at aa 284 of HEF, was
thought to be responsible for this phenotype (50).
Based on Szepanski’s work, we decided to generate a HEF
284 Ile mutant of C/JHB/1/66 (referred to as 284 virus) by
reverse genetics and to test its phenotype. Along with the
introduction into plasmid pC/PR/HEF/JHB of the desired
nonsilent mutation at nt 872 of the HEF sequence, we also
introduced a silent mutation at nt 870 to generate an EcoRV
restriction site (Table 2).
Based on the observation of a single difference at aa 465
between our sequence and the previously published (14) se-
quences of the C/JHB/1/66 HEF protein, we replaced the Thr
codon found in our sequence with an Ala codon as described
by Hanika et al. (14) (465 mutant) and also introduced a new
restriction site at that position. For this purpose, two nonsilent
(nt 1414 and 1416) nucleotide mutations and one silent (nt
1419) nucleotide mutation were introduced into the cDNA of
plasmid pC/PR/HEF/JHB, resulting in the desired amino acid
substitution and the creation of a NgoMIV restriction site
(Table 2). Finally, a double mutant (284465 mutant) was also
constructed by subcloning to study whether these mutations
have independent effects or not.
As for the rescued wild-type influenza C virus, the rescued
mutant viruses were detected in the supernatant of transfected
cells at 9 or 10 days posttransfection. They could easily be
titrated by plaque assay, either directly (data not shown) or
upon amplification in embryonated eggs and exhibited a
plaque phenotype similar to that of the C/JHB/1/66 reference
virus (Fig. 1). The titers obtained varied for each mutant but
were in a range close to that of the rescued wild-type virus
(Table 1). The rescued mutant viruses were then amplified on
SK 93/2 cells at an MOI of 103 to reach titers between 105 and
107 PFU/ml at 5 days postinfection (data not shown). After five
consecutive passages on SK 93/2 cells, the stability of the res-
cued mutant viruses was analyzed by RT-PCR followed by
restriction enzyme digestion as described in Material and
Methods. No amplification was observed for water and mock-
infected cells supernatant used as negative controls (Fig. 2,
lanes a and f, respectively). The expected 875-nt-long amplicon
was observed when the vRNA expression plasmids for HEF
and its mutants were used as templates for PCR (Fig. 2A, lanes
b to e). With RNA from cells infected with rescued viruses, no
TABLE 2. Substitutions introduced into the HEF protein of
C/JHB/1/66 and enzyme restriction strategy used to
analyze the stability of the rescued mutants
Virus
description
Amino acid
position
Amino
acid
Nucleotide
sequenceb
Restriction
site
After
digestionc
wta 284 Thr GAC ACC None 875
465 Thr ACA GGA None 875
Mutants 284 Ile GAT ATC EcoRV 694  181
465 Ala GCC GGC NgoMIV 727  148
a Wild type.
b Underlined, nucleotide codons coding for the indicated amino acid; in bold,
nonsilent mutations; in italics, silent mutations introduced in the neighboring
codons to design a restriction enzyme site.
c Expected length(s) (nt) of fragment(s) produced after digestion of amplicons
with the indicated restriction enzymes.
FIG. 1. Plaque phenotype of the C/JHB/1/66 wild type (wt), res-
cued wild type (rwt), and mutant (465, 284, and 284465) viruses.
Viruses amplified on embryonated eggs were titrated by plaque assay
on MDCK II cells pretreated with BBG as described in Materials and
Methods.
FIG. 2. Genetic stability of rescued HEF mutants. The HEF mu-
tants of C/JHB/1/66 were engineered to carry genetic markers. For
each rescued virus, vRNA was extracted from virus particles after five
passages on SK 93/2 cells at a MOI of 103 (lanes g to j). Amplification
by RT-PCR was performed with primers specific for the HEF se-
quences flanking the mutated region (B). Amplification was performed
in parallel on water (lane a) and with samples derived from the mock-
transfected cell supernatant (lane f) as negative controls and on the
counterpart vRNA expression plasmids (lanes b to e) as positive con-
trols. After purification, PCR products were digested with EcoRV
(C) or NgoMIV (D). A control reaction was carried out in the absence
of reverse transcriptase (A) in order to ensure that the amplification
product was derived from vRNA and not from plasmid carried over
from transfected cells. Lanes b and g, wt virus; lanes c and h, 465 Ala
mutant; lanes d and i, 284 Ile mutant; lanes e and j, 284 Ile and 465 Ala
double mutant.
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amplification was observed without reverse transcription, thus
ensuring the absence of plasmids carried over from trans-
fected/infected cells (Fig. 2A, lanes g to j). After RT-PCR, the
expected 875-nt-long amplicon was obtained (Fig. 2B, lanes g
to j). Only the PCR products of the 284 and the 284465
mutants were cleaved by EcoRV (Fig. 2C, lanes d, e, i, and j),
as were those of the 465 and 284465 mutants by NgoMIV
(Fig. 2D, lanes c, e, h, and j). This confirmed that the rescued
mutant viruses were stable after five passages on SK 93/2 cells.
Furthermore, the nucleotide sequences were confirmed
around amino acid positions 284 and 465 for the four rescued
viruses (data not shown).
Effect of the Thr 465 Ala and Thr 284 Ile mutations in the
HEF protein. To analyze the effect of the substitutions at aa
284 and 465 in the HEF protein, determination of growth
kinetics was performed with MDCK II cells treated or not with
BBG in the presence of a low concentration of TPCK-trypsin
(0.25 g/ml).
As expected, treatment of the cells with BBG was found to
be essential for infection by the wild type as well as rescued
wild-type or mutant viruses (Fig. 3). On cells pretreated with
BBG, the wild-type C/JHB/1/66 reference and rescued viruses
showed similar growth (Fig. 3A). Furthermore, rescued wild-
type and mutant viruses grew with essentially the same kinetics
up to 2 days postinfection (Fig. 3B). Interestingly, for both
viruses harboring an Ala at position 465 in HEF (465 and
284465 viruses), the titers were 10-fold higher than those
obtained for both viruses with a Thr 465 (rescued wild-type and
284 viruses) once the plateau phase was reached (after 3 days
postinfection).
Since Szepanski et al. (50, 51) had shown that the Thr 284 Ile
mutation enabled the growth of influenza C virus on untreated
MDCK II cells in the presence of a high concentration of
trypsin, we compared the ability of each of the four rescued
viruses to grow on MDCK II cells without pretreatment with
BBG and in the presence of a low (0.25 g/ml) or high (5
g/ml) concentration of TPCK-trypsin (51). As already
mentioned, in the presence of a low concentration of TPCK-
trypsin, pretreatment with BBG was necessary to allow in-
fection by the four rescued viruses (Fig. 4). For the wild-type
reference and rescued viruses no significant difference in
titer was observed when using a low or high concentration of
TPCK-trypsin (data not shown). In contrast, in the presence
of a high concentration of TPCK-trypsin, titers obtained for
both viruses harboring an Ile at position 284 in HEF (284
and 284465 viruses) were 100-fold higher than those for
their respective counterparts with a Thr at position 284
(rescued wild-type and 465 viruses) (Fig. 4). These results
thus further demonstrated that the Thr 284 Ile substitution
in the HEF is necessary and sufficient to enable influenza C
virus to grow on MDCK II cells in the absence of BBG if a
high concentration of trypsin is used. Furthermore, it could
be noted that the two mutations introduced in the HEF
proteins have independent effects on the growth of influenza
C virus. On the whole, our results showed that the reverse-
FIG. 3. Growth kinetics of the wild type (A), rescued wild type
(rwt) (A and B), or HEF mutant (B) virus. Confluent monolayers of
BBG-treated (solid lines) or untreated (dotted lines) MDCK II cells
were infected in duplicate in the presence of 0.25 g/ml of TPCK-
trypsin at an MOI of 103 with viruses amplified on embryonated eggs
(A) or SK 93/2 cells (B). At the indicated time points, the supernatants
were collected and virus titers were determined by plaque assay as
described in Materials and Methods. Viruses: x, wild type; diamonds,
rescued wild type; triangles, 284 Ile mutant; squares, 465 Ala mutant;
circles, double mutant. Each result is expressed as the mean of the two
infections and is representative of two independent experiments.
FIG. 4. Trypsin phenotype of the rescued wild-type or HEF mutant
virus. MDCK II cells were infected in triplicate at an MOI. of 103,
with each of the four rescued viruses as indicated in three different
conditions. MDCK II cells were either treated (gray bars) or not (open
and black bars) by BBG before infection and, after infection, further
incubated in the presence of 0.25 g/ml (open and gray bars) or 5
g/ml (black bars) of TPCK-trypsin. Four days after infection, the
supernatants were harvested and virus titers were determined by
plaque assay as described in Materials and Methods. Each result us
expressed as the mean for the three infections and is representative of
two independent experiments.
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genetics system described provides an efficient means to
perform site-directed mutagenesis of the HEF sequence of
influenza C virus.
DISCUSSION
Reverse-genetics systems have been previously described
only for the type A and B influenza viruses but not for type C.
This may be due at least in part to the fact that the complete
NC sequences for a given influenza C virus had not been
determined and to difficulties related to the type of cells to use,
the method of detecting and titrating the type C virus, and the
delay before the appearance of rescued virions.
The first influenza virus reverse-genetics system described
consisted in the rescue of a vRNA segment produced from
recombinant plasmid DNA in the presence of a helper virus
(10, 25). These experiments paved the way for the rescue of
type A influenza virus entirely from cloned cDNA. This was
first successful with the trypsin-independent A/WSN/33 strain,
for which the authors could use the very efficiently transfect-
able 293T (11, 35) or Vero cells (41). The system was later
improved by making use of a coculture of 293T cells with the
highly infectible MDCK cells (21), also allowing the engineer-
ing of trypsin-dependent type A influenza viruses. For the type
B influenza virus, the system was developed using a coculture
of the trypsin-resistant, efficiently transfectable COS7 cells
with MDCK cells (20). To set up our reverse-genetics system
for the type C influenza virus, we first thought of using cells
that are sensitive to type C influenza virus infection. The SK
93/2 cell line, which is highly infectible by type C influenza virus
(data not shown), proved to be poorly transfectable by a green
fluorescent protein control plasmid, whatever the transfectant
agent (FUGENE 6 [Roche], Lipofectamine 2000 [Invitrogen],
or Jet PEI [Ozyme]) used (data not shown). Therefore, con-
ditions were developed that allowed efficient growth of influ-
enza C virus on the highly transfectable 293T cells.
The second technical problem was related to the detection
and titration of the influenza C virus produced by reverse
genetics. Usually authors use a red-blood-cell hemagglutina-
tion test (17), which detects both virion particles and HEF
released in the supernatant. We developed a plaque assay
based on the method used for influenza A virus (52). It was not
possible to use the SK 93/2 cells, because they are not adherent
enough, and only MDCK II cell monolayers remained intact
when the agarose overlay was removed before staining with
crystal violet (data not shown). Their resistance to infection
with type C influenza virus was successfully overcome by coat-
ing the cells with BBG, which naturally contain Neu5,9Ac2 (17)
and allowed the development of a reproducible plaque assay
for influenza C virus on MDCK II cells (Fig. 1).
It is well known that at the optimal temperature of 33°C, the
type C influenza virus grows on susceptible cells more slowly
than type A at 35°C or type B at 33°C. Because of this slow
virus growth, contrary to the case with type A and B influenza
viruses, for which viruses rescued by reverse genetics were
detected as soon as 24 or 36 h posttransfection (20, 35), the
wild-type type C influenza virus rescued by our reverse-genet-
ics system was first detectable in the supernatant of transfected
cells only at 6 days posttransfection (data not shown), and the
maximum yield was obtained only at day nine or ten. Also, for
the titration by plaque assay, plaques of type A or B influenza
virus usually appeared after 3 days, whereas for type C, plaques
were clearly detected only after 4 or 5 days.
The reverse-genetics system we developed for influenza C
virus is efficient and might be further improved. Indeed, co-
culture of highly transfectable cells, such as 293T, COS (20), or
Vero (11) cells, with highly infectible cells, such as SK 93/2,
might help to rescue viruses more efficiently. No improvement
was observed when using 293T and SK 93/2 cells cocultured at
a 1/1 ratio (data not shown), but different ratios need to be
tested, as well as coculture with other cells permissive for
influenza C virus. Alternatively, one could try to directly trans-
fect the SK 93/2 cells by a more efficient method, such as
electroporation or nucleofection (Amaxa Biosystems). Finally,
as was done for type A and B influenza virus systems (20, 22,
34), one could wish to reduce the number of plasmids. How-
ever, to study mutations that affect the polymerase complex
(structure or activity), a system that separates the vRNA and
protein expression plasmids should be preferred for the rescue
of mutant viruses. Indeed, if the mutation introduced in the
vRNA affects the activity of the polymerase complex protein, a
system based on bidirectional plasmids might not allow the
reconstruction of functional RNPs and hence the rescue of the
mutant virus.
Using our reverse-genetics system, based entirely on plas-
mids, we successfully generated influenza C viruses with mu-
tations in the HEF protein. The Thr 465 Ala substitution
resulted in an increase of virus growth capabilities (Fig. 3 and
4). Residue 465 is located in the peptide fusion domain of the
HEF2 subunit, which is involved in the fusion of the virus
envelope and cell membranes (42). The work of Formanowski
et al. (12) indicated that amino acid substitutions involving a
change of charge in HEF2 might be responsible for the varia-
tion of the pH optimum for fusion among influenza C virus
strains. Since the Thr-to-Ala substitution replaced a polar res-
idue with a nonpolar residue, the global hydrophobicity of the
fusion peptide might be increased and the fusion capabilities of
the virus enhanced, thus explaining the difference in growth
properties. Interestingly, we also noticed that recovery of the
465 Ala viruses by reverse genetics seemed to be easier, since
the virus yields in the supernatant of the transfected cells
repeatedly reached about 104 PFU/ml at 6 days after transfec-
tion, i.e., 10- to 100-fold more than for the wild-type-like virus
at that time (data not shown). This could prove useful for
studying the positive or negative effects of mutations in any of
the seven segments on the growth and replication of influenza
C virus.
Using our reverse-genetics system, we confirmed that the
Thr 284 Ile mutation in HEF described by Szepanski et al. (50)
was associated with the capability of influenza C virus to grow
on MDCK II cells in the presence of a high concentration of
trypsin. Thr 284 in the HEF was found to be conserved in all
sequences available in the GenBank database for influenza C
virus strains isolated between 1950 and 2000. For the hemag-
glutinin of influenza A virus, it was shown that a single point
mutation can have a drastic effect on the receptor-binding
activity (47, 49). For instance, for the H1 and H3 subtypes,
position 226 in the HA was shown to determine the receptor
specificity by the recognition of 2,3-linked or 2,6-linked
sialic acids (36, 47, 53). Similarly, Suzuki et al. (49) showed that
VOL. 81, 2007 RESCUE OF INFLUENZA C VIRUS FROM RECOMBINANT DNA 11287
 o
n
 January 15, 2015 by INSTITUT PASTEUR Bibliothèque
http://jvi.asm.org/
D
ow
nloaded from
 
position 205 in H1 can on its own influence the binding spec-
ificity. The substitution at residue 193 of H3 altered the bind-
ing of the hemagglutinin from human or equine influenza A
viruses (32). The Thr 284 Ile substitution in the HEF protein of
influenza C virus was described by Szepanski et al. for a mutant
virus obtained by passaging C/JHB/1/66 on MDCK II cells in
the presence of a high concentration of trypsin (50, 51). Our
results further demonstrated that the Thr 284 Ile substitution
is necessary and sufficient to enable influenza C virus to grow
on MDCK II cells at a high concentration of trypsin in the
absence of BBG. Based on adhesion assays on ganglioside-
treated red blood cells (50), it was suggested that an Ile at
position 284 would enhance the affinity of HEF for the
Neu5,9Ac2 sialic acid receptor. Since position 285 of HEF was
found to be directly involved in receptor binding (48), it is
possible that an Ile at position 284 induces a conformational
change in the structure of the receptor-binding pocket. How-
ever, how and where the trypsin acts in this process is not clear
at present. It seems rather unlikely that a high concentration of
trypsin could improve the cleavage of HEF, since similar ef-
fects would be expected irrespective of the nature of the resi-
due at position 284. It is then possible that another low-affinity
cleavage site, which would be recognized by trypsin, could be
revealed by a change of conformation of the HEF protein of
284 Ile viruses. This would in turn lead to changes in the HEF
properties that could be involved in the observed growth phe-
notype. Alternatively, trypsin at a high concentration could act
on the MDCK II cells and unmask Neu5,9Ac2 sialic acids that
would be present in very small amounts on the MDCK II cells.
This could explain why only the 284 Ile viruses, with their
enhanced HEF affinity for the receptor, would grow in these
conditions.
Our system for influenza C virus completes the series of
reverse-genetics systems for the different genera of the Ortho-
myxoviridae family. While this paper was under review, a sim-
ilar system was described for type C influenza virus C/Ann
Arbor/1/50 by Muraki et al. (33). These will prove extremely
helpful for addressing a number of questions in the field of
influenza virus research, with a particular interest for the type
specificity requirements. Having the technology to introduce
any viable mutation into the influenza C virus genome will
enable us to study the viral life cycle and its regulation, the
structure-function relationships of the different viral proteins,
or the molecular mechanisms of viral pathogenicity (notably
the limited pathogenicity recorded for influenza C virus). Fi-
nally, one could try to engineer influenza C viruses to generate
expression vectors, which could then be used as live vaccines.
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